Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | FABP6 | P51161 | 1/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469482 | 1.00 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| Hydrochloric Acid SCHEMBL2360497 | 0.98 | ALDH1A1 (0.61) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL19744586 | 0.89 | MAPT (0.50) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL30054665 | 0.85 | FABP6 (0.56) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL1859632 | 0.85 | FABP6 (0.56) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL8471521 | 0.80 | FABP6 (0.42) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL18708235 | 0.77 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL2933658 | 0.77 | ALDH1A1 (1.00) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL33867 | 0.77 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10FABP6 | |
| SCHEMBL30895878 | 0.77 | MAPT (0.62) | ALDH1A1GAAMAPTHSD17B10FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | claimed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114206443-B | Aromatic or heteroaromatic ring derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4125861-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220227699-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | WYETH (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042735-A1 | TETRAHYDROQUINOLINE, INDOLINE, AND RELATED ANILINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | ALDH1A1 2834/4885GAA 4469/4885MAPT 4586/4885 |
| US-20220227699-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | AGTR2, AGTR1, AVPR2 | ALDH1A1 765/4885GAA 3024/4885MAPT 3087/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | ALDH1A1 1867/4885GAA 4842/4885MAPT 4529/4885 |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | ALDH1A1 1306/4885GAA 1938/4885MAPT 962/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | ALDH1A1 605/4885GAA 3626/4885MAPT 552/4885 |
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, HTR2C, HTR3A | ALDH1A1 1655/4885GAA 4570/4885MAPT 241/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | ALDH1A1 3889/4885GAA 3615/4885MAPT 1086/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | ALDH1A1 1553/4885GAA 3500/4885MAPT 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.